Novo's Amylin Injectable Cagrilintide Hits 11.8% Weight Reduction in Phase III Trial BioSpace EASD25: In search of Wegovy successor, Novo touts cagrilintide tolerability Novo Nordisk's CagriSema Drug Trial Data Falls Short Again Shares Plunge by 8 Percent CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current Based on the early promising data for injectable cagrilintide semaglutide combination for #obesity #T2D @novonordisk move to test an oral GLP 1 Amylin Amycretin peptide in healthy PPL with overweight and #obesity in P1 Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination